Update on medical therapy for obscure gastrointestinal hemorrhage;Avances en el tratamiento farmacológico de la hemorragia digestiva de origen oscuro

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 8, 2007, Pages 457-462

  Molina Infante, Javier ^a   Perez Gallardo B ^a   Fernandez Bermejo M ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Angiodysplasia; Beta blockers; Hormonal therapy; Medical therapy; Obscure gastrointestinal haemorrhage; Octreotide; Octreotide LAR; Thalidomide

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DANAZOL; DESMOPRESSIN; ETHINYLESTRADIOL; NORETHISTERONE; OCTREOTIDE; PLACEBO; RECOMBINANT BLOOD CLOTTING FACTOR 7A; SOMATOSTATIN DERIVATIVE; THALIDOMIDE; TRANEXAMIC ACID;

ANGIODYSPLASIA; BLEEDING; CAPSULE ENDOSCOPY; DIGESTIVE SYSTEM HEMORRHAGE; DOUBLE BALLOON ENTEROSCOPY; DRUG EFFICACY; DRUG SAFETY; HORMONAL THERAPY; HUMAN; LONG TERM CARE; PORTAL HYPERTENSION; PROPHYLAXIS; REVIEW; TREATMENT INDICATION;

GASTROINTESTINAL HEMORRHAGE; HUMANS;

EID: 38349065336     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Manabe N, Tanaka S, Fukumoto A, Nakao M, Kamino D, Chayama K. Double ballon enteroscopy in patients with GI bleeding of obscure origin. Gastrointest Endosc 2006; 64: 135-40.
2. Lai LH, Wong GL, Chow DK, Lau JY, Sung JJ, Leung WK. Long term follow up of patients with obscure gastrointestinal bleeding after negative capsule endoscopy. Am J Gastroenterol 2006; 101: 1224-9.
3. Hadithi M, Heine GD, Jacobs MA, van Bodegraven AA, Mulder CJ. A prospective study comparing video capsule endoscopy with double-balloon enteroscopy in patients with obscure gastrointestinal bleeding. Am J Gastroenterol 2006; 101: 52-7.
4. Matas JL, Asteinza M, Loscos JM, Fernández S, Ramírez Armengol JA, Díaz Rubio M. Diagnostic yield and safety of capsule endoscopy. Rev Esp Enferm Dig 2006; 98: 666-73.
5. Pérez Cuadrado E, Mas P, Hallal H, Shanabo J, Muñoz E, Ortega I, et al. Double-balloon enteroscopy: A descriptive study of 50 explorations. Rev Esp Enferm Dig 2006; 98: 73-81.
6. Zuckerman GR, Prakash C, Ashkin MP, Lewis BS. AGA technical review: Evaluation and management of occult and obscure gastrointestinal bleeding. Gastroenterology 2000; 118: 20.
7. Coppola A, Di Stefano V, Tufano A, Nardone G, Amoriello M, Cerbone AM, et al. Long lasting intestinal bleeding in an old patient with multiple vascular abnormalities and Glanzmann's thromboasthenia: 3-year pharmacological management. J Int Med 2002: 252: 271-5.
8. Krikis N, Tziolamos K, Perifanis V, Vakalopoulou S, Karagiannis A, Garipidou, et al. Treatment of recurrent gastrointestinal haemorhage in a patient with von Willebrand's disease with octreotide LAR and propanolol. Gut 2005; 54: 171.
9. Harrison DF. Use of estrogen in treatment of familial hemorrhagic telangiectasia. Laryngoscope 1982; 92: 314-20.
10. Panes J, Casadevall M, Fernandez M, Pique JM, Bosch J, Casamitjana R, et al. Gastric microcirculatory changes of portal hypertensive rats can be attenuated by long-term estrogen-progesterone treatment. Hepatology 1994; 20: 1261-70.
11. Nguyen L, Liles DR, Lin PH, Bush RL. Hormone replacement therapy and peripheral vascular disease in women. Vasc Endovascular Surg 2004; 38: 547-56.
12. Van Cutsem E, Rutgeerts P, Vantrappen G. Treatment of bleeding gastrointestinal vascular malformations with oestrogen-progesterone. Lancet 1990; 335: 953-5.
13. Lewis B, Salomon P, Rivera MacMurray S, Kornbluth A, Wenger J, Wayne J. Does hormonal therapy have any benefit for bleeding angiodysplasia? J Clin Gastroenterol 1992; 15: 99-103.
14. Junquera F, Feu F, Papo M, Videla S, Armengol JR, Bordas JM, et al. A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology 2001; 121: 1073-9.
15. Madanick RD, Barkin JS. Hormonal therapy in angiodysplasia: Should we completely abandone its use? Gastroenterology 2002; 123: 2156.
16. Hodgson H. Hormonal therapy for gastrointestinal angiodysplasia. Lancet 2002; 359: 1630-1.
17. Manzanera MJ, Gutiérrez E, Domínguez Gil B, García JA, González E, Praga M. Hemorragia digestiva por angiodisplasia en pacientes en hemodiálisis. Tratamiento con estrógenos conjugados. Nefrologia 2005; 25: 412-5.
18. Tran A, Villeneuve JP, Bilodeau M, Willems B, Marleau D, Fenyves D, et al. Treatment of chronic gastric bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: An open pilot study. Am J Gastroenterol 1994; 94: 2909-11.
19. Burak KW, Lee SS, Beck PL. Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001; 49: 866-72.
20. Yoshie K, Fujita Y, Moriya A, Kanawa I, Miyamoto Y, Umemura S. Octreotide for severe acute bleeding from portal hypertensive colopathy: A case report. Eur J Gastroenterol Hepatol 2001; 13: 1111-3.
21. Bowers M, McNulty O, Mayne E. Octreotide in the treatment of gastrointestinal bleeding caused by angiodisplasia in two patients with von Willebrand's disease. Br J Hematol 2000; 108: 524-7.
22. Nordquist LT, Wallach PM. Octreotide for obscure gastrointestinal bleeding in an anticoagulated patient. Dig Dis Sci 2002; 47: 1514-5.
23. Blich M, Fruchter O, Edelstein S, Edoute Y. Somatostatin therapy ameliorates chronic and refractory gastrointestinal bleeding caused by diffuse angiodysplasia in a patient on anticoagulation therapy. Scand J Gastroentrerol 2003; 38: 81-3.
24. Nardone G, Rocco A, Balzano T, Budillon G. The efficacy of octreotide therapy in crhonic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-36.
25. Rivera M, Lucero J, Guerrero A, Márquez JL, Montes R, Suner M, et al. Octreotide in the treatment of angiodysplasia in patients with advanced chronic renal failure. Nefrología 2005; 25: 332-5.
26. Kaza Z, Gursel T, Dalgic B, Aslan D. Gastric angiodysplasia in a child with Bernard-Soulier syndrome: Efficacy of octreotide in longterm management. Pediat Hematol Oncol 2005; 22: 223-7.
27. Junquera F, Saperas S, Videla S, Feu F, Vilaseca J, Armengol JR, et al. Long-term efficacy of octreotide in the prevention of recurrent bleeding from gastrointestinal angiodysplasia. Am J Gastroenterol 2007; 102: 254-60.
28. Orsi P, Guatti-Zuliani C, Okolicsanyi L. Long-acting octreotide is effective in controlling rebleeding angiodysplasia of the gastrointestinal tract. Dig Liver Dis 2001; 33: 330-4.
29. Tamagno G, Mioni R, De Carlo E, Maffei P, Rubello D, Sicolo N. Effects of a somatostatin analogue in occult gastrointestinal bleeding: a case report. Dig Liver Dis 2004; 36: 843-6.
30. Molina Infante J, Pérez Gallardo B, González García G, Fernández Bermejo M, Mateos Rodríguez JM, Robledo Andrés P. Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy. Gut 2007; 56: 447.
31. Scwartz J, Rozenfeld V, Habot H. Cessation of recurrent bleeding from gastrontestinal angiodysplasia after beta blocker treatment in a patient with a hypertrophic subaortic stenosis: a case history. Angiology 1992; 43: 244-8.
32. Karajeh MA, Hurlstone DP, Stephenson TJ, Ray-Chaudhuri D, Gleeson DC. Refractory bleeding from portal hypertensive gastropathy: A further novel role for thalidomide therapy? Eur J Gastroenterol Hepatol 2006; 18: 545-8.
33. Craanen ME, van Triest B, Verjeihen RH, Mulder CJ. Thalidomide in refractory haemorrhagic radiation induced proctitis. Gut 2006; 55: 1371-2.
34. Hirri HM, Green PJ, Lindsay J. Von Willebrand's disease and angiodysplasia treated with thalidomide. Haemophilia 2006; 12: 285-6.
35. Shurafa M, Kamboj G. Thalidomide for the treatment of bleeding angiodysplasias. Am J Gastroenterol 2003; 98: 221-2.
36. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53: 609-12.
37. De Konig DB, Drenth JP, Friederich P, Nagengast FM. Thalidomide for the treatment of recurrent gastrointestinal blood loss due to intestinal angiodysplasias. Ned Tijdschr Geneeskd 2006; 150: 1994-7.
38. Kirhkam SA, Lindley KJ, Elawad MA, Blanshard C, Shah N. Treatment of multiple small bowel angiodysplasias causing severe life-threatening bleeding with thalidomide. J Pediatr Gastroenterol Nutr 2006; 42: 585-7.
39. Bauditz J, Lochs H, Voderholzer W. Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. Endoscopy 2006; 38: 1036-9.
40. Hussain I, Saba, Genevieve A. Morelli, Luis A. Logrono. Brief report: Treatment of bleeding in hereditary hemorrhagic telangiectasia vith aminocaproic acid. N Engl J Med 1994; 330: 1789.
41. Philips MD. Stopping bleeding in hereditary telangiectasia. N Engl J Med 1994; 330: 1822-3.
42. Bojan Vujkovac, Janez Lavre, Miso Sabovic. Successful treatment of bleeding from colonic angiodysplasias with tranexamic acid in a hemodialisis patient. Am J Kidney Diseases 1998; 3: 536-8.
43. Haq AU, Glass J, Netchvolodoff CV, Bowen LM. Hereditary hemorrhagic telangiectsia and danazol. Ann Intern Med 1988; 109: 171.
44. Korzenik J, Topazian M, Burdge C, White RI. Danazol in the treatment of GI hemorrhage secondary to hereditary hemorrhagic telangiectasia (abstract). Gastroenterol 1995; 108: A297.
45. Quitt M, Froom P, Veisler A, Falber J, Sova J, Aghai E. The effect of desmopressin on masive gastrointestinal bleeding in hereditary telangiectasia unresponsive to treatment with cryoprecipitate. Arch Intern Med 1990; 150: 1744-6.
46. Romero Castro R, Jiménez Sáenz M, Pellicer Bautista M, Gómez Parra M, Arguelles Arias F, Guerrero Aznar MD, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from esophageal varices. Clin Gastroenterol Hepatol 2004; 2: 78-84.
47. Bosch J, Tabut D, Bendtsen F, D'Amico G, Albillos A, González Abraldes J, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: A randomized, double-blind trial. Gastroneterology 2004; 127: 1123-30.
48. Tonkic A, Jukic I, Titlic M, Mise S. Successful treatment of massive acute upper gastrointestinal bleeding in liver failure with activated recombinant factor VII (NovoSeven): A case report. Blood Coagul Fybrinolisis 2005; 16: 385-7.
49. Romero Castro R, Jiménez Sáenz M, Pellicer-Bautista F, Herrerías Gutiérrez JM. Refractory bleeding after endoscopic sphincterotomy: A new indication for recombinant factor VII therapy? Am J Gastroenterol 2004; 99: 2063-5.
50. Meijer K, Peters FT, van der Meer J. Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa. Blood Coagul Fybrinolisis 2001; 12: 211-3.
51. Basso IN, Keeling D. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fybrinolisis 2005; 15: 503-4.
52. Alkyldiz M, Turan I, Ozutemiz O, Batur Y, Ilter T. A cerebrovascular event after single-dose administration of recombinant factor VIIa in a patient with esophageal variceal bleeding. Dig Dis Sci 2006; 51: 1647-9.